上海科技大学知识管理系统

The present disclosure provides compositions and methods for preparing and using individualized patient-derived tumor organoids (IPTO). Human iPSC-derived cerebral organoids can be used as hosts for tumor tissue grafts. Patient materials can be obtained directly after surgery and dissected into small pieces. The small tumor tissue is inserted into the cerebral organoid to prepare a hybrid organoid. This hybrid organoid can grow for several weeks to months, allowing even slow-growing tumors, such as glioma with IDH mutations and pilocytic astrocytoma, to proliferate. The tumor pieces preferably include both tumor cells and adjacent stromal cells, allowing testing of conventional chemotherapeutic agents as well as immunotherapeutic agents.

本公开内容提供了用于制备和使用个体化患者衍生的肿瘤类器官(IPTO)的组合物和方法。 人iPSC来源的脑类器官可用作肿瘤组织移植物的宿主。 患者材料可在手术后直接获得并解剖成小块。 将小肿瘤组织插入脑类器官，制备杂交类器官。 这种杂合类器官可以生长几周到几个月，使得即使是生长缓慢的肿瘤，例如具有IDH突变的神经胶质瘤和毛细胞星形细胞瘤也能够增殖。 肿瘤块优选包括肿瘤细胞和相邻的基质细胞，从而允许测试常规化疗剂以及免疫治疗剂。